Please enable JavaScript to continue using this application.

Compare $CGON vs $PTCT | Chartloom

Compare

$CGON vs $PTCT

CG Oncology Inc · PTC Therapeutics Inc

CGON

CG Oncology Inc

PTCT

PTC Therapeutics Inc

Compare $CGON vs $PTCT

Comparing CG Oncology Inc and PTC Therapeutics Inc

CGONCG Oncology Inc

PTCTPTC Therapeutics Inc

CGONCG Oncology Inc

Market cap

$5.63B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

135.78x

Rev growth (TTM)

1030.3%

YTD performance

52.7%

52W performance

56.8%

FCF yield

-3.2%

PTCTPTC Therapeutics Inc

Market cap

$5.37B

P/E (TTM)

—

Forward P/E (NTM)

43.00x

Forward P/S (NTM)

4.18x

Rev growth (TTM)

-36.7%

YTD performance

-15.7%

52W performance

0.3%

FCF yield

-0.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CGON

PTCT

Detailed metrics comparison

CGON

CG Oncology Inc

PTCT

PTC Therapeutics Inc

Market Cap

CGON$5.63B

PTCT$5.37B

Enterprise Value

CGON$5.61B

PTCT$7.24B

Price

CGON$63.82

PTCT$64.70

P/E Ratio

CGONN/A

PTCTN/A

P/S Ratio

CGON903.81x

PTCT5.32x

EV/Sales

CGON901.14x

PTCT7.17x

EV/EBITDA

CGON0.00x

PTCT35.21x

P/B Ratio

CGON5.80x

PTCT3,530.95x

P/FCF Ratio

CGONN/A

PTCTN/A

EV/FCF

CGON-31.29x

PTCT-182.20x

PEG Ratio

CGONN/A

PTCTN/A

Forward P/E (NTM)

CGONN/A

PTCT43.00x

Forward P/S (NTM)

CGON135.78x

PTCT4.18x

Revenue (TTM)

CGON$6M

PTCT$1.01B

Revenue Growth (YoY)

CGON1030.3%

PTCT-36.7%

Forward Rev Growth

CGON1916.0%

PTCT11.6%

Gross Margin (TTM)

CGON-85.2%

PTCT93.0%

Operating Margin (TTM)

CGON0.0%

PTCT12.4%

EBITDA Margin (TTM)

CGON-4008.7%

PTCT17.1%

Net Margin (TTM)

CGON-3602.7%

PTCT-3.8%

FCF Margin (TTM)

CGON-2879.6%

PTCT-3.9%

Net Income (TTM)

CGON$-224M

PTCT$-38M

FCF (TTM)

CGON$-179M

PTCT$-40M

EPS (TTM)

CGON-$2.54

PTCT-$0.42

ROE (TTM)

CGON-2520.0%

PTCT-35191.0%

ROA (TTM)

CGON-2398.0%

PTCT-132.0%

ROIC (TTM)

CGON-2512.0%

PTCT-3977.0%

Cash

CGON$20M

PTCT$1.05B

Debt

CGON$3M

PTCT$2.92B

Net Cash/Debt

CGON$17M

PTCT$-1.87B

Current Ratio (TTM)

CGON22.22x

PTCT3.39x

Quick Ratio (TTM)

CGON21.78x

PTCT3.20x

Debt/Equity (TTM)

CGON0.00x

PTCT848.93x

Debt/Assets (TTM)

CGON0.0%

PTCT0.0%

Interest Coverage (TTM)

CGONN/A

PTCTN/A

Net Debt/EBITDA (TTM)

CGON0.00x

PTCT0.00x

Beta

CGON0.25

PTCT0.50

52W Performance

CGON56.8%

PTCT0.3%

YTD Performance

CGON52.7%

PTCT-15.7%

% from 52W High

CGON-21.2%

PTCT-28.8%

% from 52W Low

CGON78.3%

PTCT5.7%

Asset Turnover (TTM)

CGON0.01x

PTCT0.35x

FCF Yield (TTM)

CGON-3.2%

PTCT-0.7%

Earnings Yield (TTM)

CGON-4.0%

PTCT-0.7%

Dividend Yield (TTM)

CGONN/A

PTCTN/A

Rule of 40

CGON-1,849.3

PTCT-40.7

EV/GP/RG

CGONN/A

PTCT0.24

Ticker research

View CGON research View PTCT research

Metric	CGON CG Oncology Inc	PTCT PTC Therapeutics Inc
Market & Valuation
Market Cap	$5.63B	$5.37B
Enterprise Value	$5.61B	$7.24B
Price	$63.82	$64.70
P/E Ratio	N/A	N/A
P/S Ratio	903.81x	5.32x
EV/Sales	901.14x	7.17x
EV/EBITDA	0.00x	35.21x
P/B Ratio	5.80x	3,530.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-31.29x	-182.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	43.00x
Forward P/S (NTM)	135.78x	4.18x
Revenue & Growth
Revenue (TTM)	$6M	$1.01B
Revenue Growth (YoY)	1030.3%	-36.7%
Forward Rev Growth	1916.0%	11.6%
Profitability
Gross Margin (TTM)	-85.2%	93.0%
Operating Margin (TTM)	0.0%	12.4%
EBITDA Margin (TTM)	-4008.7%	17.1%
Net Margin (TTM)	-3602.7%	-3.8%
FCF Margin (TTM)	-2879.6%	-3.9%
Net Income (TTM)	$-224M	$-38M
FCF (TTM)	$-179M	$-40M
EPS (TTM)	-$2.54	-$0.42
ROE (TTM)	-2520.0%	-35191.0%
ROA (TTM)	-2398.0%	-132.0%
ROIC (TTM)	-2512.0%	-3977.0%
Financial Health
Cash	$20M	$1.05B
Debt	$3M	$2.92B
Net Cash/Debt	$17M	$-1.87B
Current Ratio (TTM)	22.22x	3.39x
Quick Ratio (TTM)	21.78x	3.20x
Debt/Equity (TTM)	0.00x	848.93x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.25	0.50
52W Performance	56.8%	0.3%
YTD Performance	52.7%	-15.7%
% from 52W High	-21.2%	-28.8%
% from 52W Low	78.3%	5.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.35x
FCF Yield (TTM)	-3.2%	-0.7%
Earnings Yield (TTM)	-4.0%	-0.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,849.3	-40.7
EV/GP/RG	N/A	0.24
Ticker research	View CGON research	View PTCT research

Valuation

P/S Ratio

PTCT

5.32x

CGON

903.81x

EV/FCF

PTCT

-182.20x

CGON

-31.29x

Growth & revenue

Revenue Growth TTM

CGON

1030.3%

PTCT

-36.7%

Forward Revenue Growth

CGON

1916.0%

PTCT

11.6%

Profitability & performance

Gross Margin

PTCT

93.0%

CGON

-85.2%

ROE

CGON

-2520.0%

PTCT

-35191.0%

FCF Yield %

PTCT

-0.7%

CGON

-3.2%

52-Week Performance

CGON

56.8%

PTCT

0.3%

Detailed metrics comparison

CGON

CG Oncology Inc

PTCT

PTC Therapeutics Inc

Market Cap

CGON$5.63B

PTCT$5.37B

Enterprise Value

CGON$5.61B

PTCT$7.24B

Price

CGON$63.82

PTCT$64.70

P/E Ratio

CGONN/A

PTCTN/A

P/S Ratio

CGON903.81x

PTCT5.32x

EV/Sales

CGON901.14x

PTCT7.17x

EV/EBITDA

CGON0.00x

PTCT35.21x

P/B Ratio

CGON5.80x

PTCT3,530.95x

P/FCF Ratio

CGONN/A

PTCTN/A

EV/FCF

CGON-31.29x

PTCT-182.20x

PEG Ratio

CGONN/A

PTCTN/A

Forward P/E (NTM)

CGONN/A

PTCT43.00x

Forward P/S (NTM)

CGON135.78x

PTCT4.18x

Revenue (TTM)

CGON$6M

PTCT$1.01B

Revenue Growth (YoY)

CGON1030.3%

PTCT-36.7%

Forward Rev Growth

CGON1916.0%

PTCT11.6%

Gross Margin (TTM)

CGON-85.2%

PTCT93.0%

Operating Margin (TTM)

CGON0.0%

PTCT12.4%

EBITDA Margin (TTM)

CGON-4008.7%

PTCT17.1%

Net Margin (TTM)

CGON-3602.7%

PTCT-3.8%

FCF Margin (TTM)

CGON-2879.6%

PTCT-3.9%

Net Income (TTM)

CGON$-224M

PTCT$-38M

FCF (TTM)

CGON$-179M

PTCT$-40M

EPS (TTM)

CGON-$2.54

PTCT-$0.42

ROE (TTM)

CGON-2520.0%

PTCT-35191.0%

ROA (TTM)

CGON-2398.0%

PTCT-132.0%

ROIC (TTM)

CGON-2512.0%

PTCT-3977.0%

Cash

CGON$20M

PTCT$1.05B

Debt

CGON$3M

PTCT$2.92B

Net Cash/Debt

CGON$17M

PTCT$-1.87B

Current Ratio (TTM)

CGON22.22x

PTCT3.39x

Quick Ratio (TTM)

CGON21.78x

PTCT3.20x

Debt/Equity (TTM)

CGON0.00x

PTCT848.93x

Debt/Assets (TTM)

CGON0.0%

PTCT0.0%

Interest Coverage (TTM)

CGONN/A

PTCTN/A

Net Debt/EBITDA (TTM)

CGON0.00x

PTCT0.00x

Beta

CGON0.25

PTCT0.50

52W Performance

CGON56.8%

PTCT0.3%

YTD Performance

CGON52.7%

PTCT-15.7%

% from 52W High

CGON-21.2%

PTCT-28.8%

% from 52W Low

CGON78.3%

PTCT5.7%

Asset Turnover (TTM)

CGON0.01x

PTCT0.35x

FCF Yield (TTM)

CGON-3.2%

PTCT-0.7%

Earnings Yield (TTM)

CGON-4.0%

PTCT-0.7%

Dividend Yield (TTM)

CGONN/A

PTCTN/A

Rule of 40

CGON-1,849.3

PTCT-40.7

EV/GP/RG

CGONN/A

PTCT0.24

Ticker research

View CGON research View PTCT research

Metric	CGON CG Oncology Inc	PTCT PTC Therapeutics Inc
Market & Valuation
Market Cap	$5.63B	$5.37B
Enterprise Value	$5.61B	$7.24B
Price	$63.82	$64.70
P/E Ratio	N/A	N/A
P/S Ratio	903.81x	5.32x
EV/Sales	901.14x	7.17x
EV/EBITDA	0.00x	35.21x
P/B Ratio	5.80x	3,530.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-31.29x	-182.20x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	43.00x
Forward P/S (NTM)	135.78x	4.18x
Revenue & Growth
Revenue (TTM)	$6M	$1.01B
Revenue Growth (YoY)	1030.3%	-36.7%
Forward Rev Growth	1916.0%	11.6%
Profitability
Gross Margin (TTM)	-85.2%	93.0%
Operating Margin (TTM)	0.0%	12.4%
EBITDA Margin (TTM)	-4008.7%	17.1%
Net Margin (TTM)	-3602.7%	-3.8%
FCF Margin (TTM)	-2879.6%	-3.9%
Net Income (TTM)	$-224M	$-38M
FCF (TTM)	$-179M	$-40M
EPS (TTM)	-$2.54	-$0.42
ROE (TTM)	-2520.0%	-35191.0%
ROA (TTM)	-2398.0%	-132.0%
ROIC (TTM)	-2512.0%	-3977.0%
Financial Health
Cash	$20M	$1.05B
Debt	$3M	$2.92B
Net Cash/Debt	$17M	$-1.87B
Current Ratio (TTM)	22.22x	3.39x
Quick Ratio (TTM)	21.78x	3.20x
Debt/Equity (TTM)	0.00x	848.93x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.25	0.50
52W Performance	56.8%	0.3%
YTD Performance	52.7%	-15.7%
% from 52W High	-21.2%	-28.8%
% from 52W Low	78.3%	5.7%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.35x
FCF Yield (TTM)	-3.2%	-0.7%
Earnings Yield (TTM)	-4.0%	-0.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,849.3	-40.7
EV/GP/RG	N/A	0.24
Ticker research	View CGON research	View PTCT research